Manatt’s Ian Spatz, a senior advisor with Manatt Health, spoke with The Hill on a recent federal court ruling concerning drug price disclosures in TV ads.
U.S. District Judge Amit P. Mehta in Washington, D.C., sided with a collective of drug companies in blocking the Trump administration’s proposed policy that would have required prescription drug manufacturers to disclose list prices in TV ads.
Spatz said he thinks the Trump administration may go to Congress in order to get drug price disclosure passed as a law.
“The idea was politically popular and easy to understand and was seen by many as a step in the right direction,” he said.
He also noted, however, that the drug companies could challenge this potential law on First Amendment grounds.
Read the article here.